153 results
Page 5 of 8
424B3
e9id7
22 Nov 13
Prospectus supplement
12:00am
8-K
EX-99
509 g7wxq19
28 Oct 13
Cellceutix Enters into New $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
12:00am
8-K
EX-10
cp9a0r
28 Oct 13
Cellceutix Enters into New $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
12:00am
8-K
EX-10
27psifvcxlfcge5a31
28 Oct 13
Cellceutix Enters into New $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
12:00am
8-K
EX-99.1
acwkplw
9 Sep 13
Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
12:00am
8-K
EX-2.1
h3wfbuahv7v
9 Sep 13
Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
12:00am
424B3
fa96rlzug za
5 Mar 13
Prospectus supplement
12:00am
8-K
EX-99.1
fsjpe62i97d68s686ysv
4 Mar 13
Cellceutix Signs with Leading Cancer Center For Licensing New Drug
12:00am
8-K
EX-99.1
ewv 8bvfk8ua
26 Dec 12
Cellceutix Comments on New York Times Article Heralding p53 Drugs as the New Age in Cancer Research
12:00am
8-K
EX-4.1
3a59v7s5po 7cve
10 Dec 12
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.1
29ri8g
10 Dec 12
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
m2ptr53 fam9
10 Dec 12
Entry into a Material Definitive Agreement
12:00am